tufts csdd impact reports

web-image.PNG

Analysis and insight into critical drug development issues. Cutting edge information. Original research. Your most reliable guide to drug development.

Tufts CSDD Impact Reports are a bi-monthly subscription-based publication presenting original research, analysis, and insights on a broad variety of topics, ranging from Tufts CSDD’s current drug development metrics analyses, to global pharmaceutical reimbursement policies. Research presented in Tufts CSDD Impact Reports have been cited in the Boston Globe, Wall Street Journal, Forbes, Time magazine, and the New England Journal of Medicine, among others.

CSDD Impact Reports are 4 pages long by design

Tufts CSDD Impact Reports make critical information readily accessible:

  • Charts and tables present key points, letting you focus on major findings.

  • Clear, concise—and brief—bulleted items highlight key findings, saving you time deciphering extensive text.

  • Explanatory sidebars and definitions ensure a shared understanding of key concepts and terms.


Single Issues

All Tufts CSDD Impact Reports are available for single issue ordering. Single issues can be purchased at $130 per issue. If you would like to request more than two issues, please contact Tufts CSDD at 617-636-2170 or email csdd@tufts.edu.

Annual subscriptions

Annual Electronic subscriptions for single users includes six (6) bi-monthly issues of the Tufts CSDD Impact Report, sent via PDF. 

Corporate Multi-Reader Subscriptions

Tufts CSDD offers both individual and corporate subscriptions to Tufts CSDD Impact Reports. Corporate subscriptions provide everyone in your department or organization immediate access to these timely reports. Priced to be cost effective, corporate subscriptions offer a significant volume discount off the annual individual subscription fee. If you are interested in a multi-reader subscription, please contact us by phone at 617-636-2170 or by email.


Tufts CSDD Impact Report Archives

2018

Global Biotech Product Development Continues its Multi-Decade Surge
November/December Vol. 20 No. 6
SUMMARY
Press Release

CNS Drugs Take 20% Longer to Develop and to Approve vs. Non-CNS Drugs
September/October Vol. 20 No. 5
SUMMARY
Press Release

Rising Protocol Complexity is Hindering Study Performance, Cost, and Efficiency
July/August, Vol. 20 No. 4
SUMMARY
Press Release

Patent-to-launch Time for Orphan Drugs is 2.3 Years Longer vs. Other Drugs
May/June, Vol. 20 No. 3
SUMMARY
Press Release

Clinical Site Initiation Process Remains Lengthy and Highly Inefficient
March/April, Vol. 20 No. 2
SUMMARY
Press Release

Clinical Data Volume and Diversity Pose Increasing Challenges and Delays
Jan/Feb, Vol. 20 No. 1
SUMMARY
Press Release

 

2017

Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time Rose
Sep/Oct, Vol. 19 No.5
SUMMARY
Press Release

Real World Evidence Use in Clinical & Post-Approval Research Set to Expand
Nov/Dec, Vol. 19 No.6
SUMMARY
Press Release

Biotech Products Accounted for 35% of All New FDA Approvals in 2000-16
May/Jun, Vol. 19 No. 3
SUMMARY
Press Release

Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies
Jul/Aug, Vol. 19 No. 4
SUMMARY
Press Release

Poor Physician and Nurse Engagement Driving Low Patient Recruitment
Jan/Feb, Vol. 19 No. 1
SUMMARY
Press Release

Approval Time for 505(b)(2) Drugs is Nearly Five Months Longer Than for NMEs
Mar/Apr, Vol. 19 No. 2
SUMMARY
Press Release


2016

Diabetes Drug Development is Riskier Compared to All Drug Development
Sep/Oct, Vol. 18 No. 5
SUMMARY
Press Release

Pediatric Regulatory Science, Clinical Trial Networks Hold Promise for Studies
Nov/Dec, Vol. 18 No. 6
SUMMARY
Press Release

Expected Growth in PBM Exclusion Lists Poses a Challenge to Drug Developers
May/June, Vol. 18 No. 3
SUMMARY
Press Release

Global Regenerative Medicine Market is Poised for Strong Growth
Jul/Aug, Vol. 18 No. 4
SUMMARY
Press Release

Amendments Reduce Number of Patients, But at High Cost, Longer Study Times
January/February, Vol. 18 No. 1
SUMMARY
Press Release

Promise of Immuno-Oncology Therapies is Boosting R&D Funding, Alliances
March/April, Vol. 18 No. 2
SUMMARY
Press Release


2015

 

Adverse Drug Event Reporting in U.S. Beset by Incompleteness and Inaccuracy
September/October, Vol. 17 No.5
SUMMARY
Press Release

First-in-Class Drugs in Competitive Development Races With Later Entrants
November/December, Vol. 17 No. 6
SUMMARY
Press Release

Personalized Medicine Gains Traction But Still Faces Multiple Challenges
May/June 2015, Vol. 17 No. 3
SUMMARY
Press Release

Vaccine Products in the R&D Pipeline Have More Than Tripled Since 2005
July/August 2015, Vol. 17 No. 4
SUMMARY
Press Release

High Turnover, Protocol Noncompliance Plague the Global Site Landscape
January/February 2015, Vol. 17 No. 1
SUMMARY
Press Release

Biosimilars Entering the U.S. Market Are Likely to Face Multiple Challenges
March/April 2015, Vol. 17 No. 2
SUMMARY
Press Release


2014

Protocol Design Optimization Starting to Improve Study Performance
September/October 2014, Vol. 16 No. 5
SUMMARY
Press Release

CNS Drugs Take Longer to Develop, Have Lower Success Rates, Than Other Drugs
November/December 2014, Vol. 16 No. 6
SUMMARY
Press Release

Collaboration & Risk-Sharing Programs Experience Longer Development Times
May/June 2014, Vol. 16 No. 3
SUMMARY
Press Release

Patients Face New Challenges Accessing a Growing Number of Orphan Drugs
July/August 2014, Vol. 16 No. 4
SUMMARY
Press Release

New Breakthrough Therapy Designation Program Aims to Cut Clinical Trial Time
January/February 2014, Vol. 16 No. 1
SUMMARY
Press Release

Drug Sponsors Tread Cautiously Using Social Media to Aid Clinical Research
March/April 2014, Vol. 16 No. 2
SUMMARY
Press Release


2013

Causes of Clinical Failures Vary Widely by Therapeutic, Phase of Study
September/October 2013, Vol. 15 No. 5
SUMMARY
Press Release

Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically
November/December 2013, Vol. 15 No. 6
SUMMARY
Press Release

Clinical Success Rates for New Cancer Drugs Double While More Enter Testing
May/June 2013, Vol. 15 No. 3
SUMMARY
Press Release

Annual Approvals for Neglected Diseases Rose from 2.6 in 2000-08 to 5 in 2009-12
July/August 2013, Vol. 15 No. 4
SUMMARY
Press Release

89% of Trials Meet Enrollment, but Timelines Slip, Half of Sites Under-Enroll
January/February 2013, Vol. 15 No. 1
SUMMARY
Press Release

Global Site Landscape Remains Highly Fragmented with Variable Performance
March/April 2013, Vol. 15 No. 2
SUMMARY
Press Release


2012

Oncology Drugs Get Faster Approvals Than Non-Oncology Drugs in U.S.
September/October 2012, Vol. 14 No. 5
SUMMARY
Press Release

One in Five Procedures Generates Extraneous Clinical Trials Data
November/December 2012, Vol. 14 No. 6
SUMMARY
Press Release

User Fee Era in U.S. Currently Poses Mixed Regulatory Burden for Sponsors
May/June 2012, Vol. 14 No. 3
SUMMARY
Press Release

U.S. Offers Patients Faster, Greater Access to Cancer Drugs Than Europe
July/August 2012, Vol. 14 No. 4
SUMMARY
Press Release

Study Monitor Workload High & Varied with Wide Disparity by Global Region
January/February 2012, Vol. 14 No. 1
SUMMARY
Press Release

Pace of CNS Drug Development and FDA Approvals Lags Other Drug Classes
March/April 2012, Vol. 14 No. 2
SUMMARY
Press Release


2011

Nearly 60% of All Protocols Require Amendments; One-Third Are Avoidable
September/October 2011, Vol. 13 No. 5
SUMMARY
Press Release

New mAbs Entering Clinical Study Rose Steadily from 1997 Through 2010
November/December 2011, Vol. 13 No. 6
SUMMARY
Press Release

Biopharmaceutical Product Approvals in the U.S. Rose Dramatically in 2000s 
May/June 2011, Vol. 13 No. 3
SUMMARY
Press Release

Lack of Clinically Useful Diagnostics Hinder Growth in Personalized Medicines
July/August 2011, Vol. 13 No. 4
SUMMARY
Press Release

U.S. Healthcare Stakeholders Uncertain on Benefits of Risk Evaluation Strategy
January/February 2011, Vol. 13 No. 1
SUMMARY
Press Release

New or Modified Indications for Existing Drugs Have Steadily Increased in U.S.
March/April 2011, Vol. 13 No. 2
SUMMARY
Press Release


2010

Clinical Approval Success Highest for Smallest Firms Among the Top 50
September/October 2010, Vol. 12 No. 5
SUMMARY
Press Release

Personalized Medicine is Playing a Growing Role in Development Pipelines
November/December 2010, Vol. 12 No. 6
SUMMARY
Press Release

Rising Protocol Complexity, Execution Burden Varies Widely by Phase and TA  
May/June 2010, Vol. 12 No. 3
SUMMARY
Press Release

Comparative Effectiveness Research Impacts Patient Access to Cancer Drugs
July/August 2010, Vol. 12 No. 4
SUMMARY
Press Release

Rising Demand is Expanding Scope and Workload of Regulatory Affairs Function
March/April 2010, Vol. 12 No. 2
SUMMARY
Press Release

U.S. Orphan Product Designations More Than Doubled from 2000-02 to 2006-08
January/February 2010, Vol. 12 No. 1
SUMMARY
Press Release


2009

Marketing Exclusivity for First–in–Class Drugs has Shortened to 2.5 years
September/October 2009, Vol. 11, No. 5
SUMMARY
Press Release

Drug Approvals for Neglected Diseases Increase Along with More R&D Funding
November/December 2009, Vol. 11 No. 6
SUMMARY
Press Release

Therapeutic Peptides in Clinical Study in 2000–07 Nearly Doubled 1990s Rate
May/June 2009, Vol. 11, No. 3
SUMMARY
Press Release

Large Pharma Success Rate for Drugs Entering Clinical Trials in 1993–04: 16%
July/August 2009 Vol. 11, No. 4
SUMMARY
Press Release

Current Investigator Landscape Poses a Growing Challenge for Sponsors
January/February 2009, Vol.11, No.1
SUMMARY
Press Release

75% of U.S. Health Plans Reimburse Off–Label Uses of Prescription Drugs
March/April 2009, Vol. 11, No. 2
SUMMARY
Press Release


2008

Fast Track Designations More Than Doubled During the Last Five Years
September/October 2008, Vol.10, No.5
SUMMARY
Press Release

While Total Approvals Decline, U.S. is Preferred Market for First Launch
November/December 2008, Vol.10, No.6
SUMMARY
Press Release

Drug Plans Non–Compliant with Medicare
May/June 2008, Vol.10, No.3
SUMMARY
Press Release

Postmarketing Studies are Becoming the Norm in U.S., Europe, and Japan
July/August 2008 Vol.10 No.4
SUMMARY
Press Release

Growing Protocol Design Complexity Stresses Investigators, Volunteers
January/February 2008, Vol.10, No.1
SUMMARY
Press Release

Number of mAbs Entering Clinical Study Nearly Tripled in Last Decade
March/April 2008, Vol.10, No.2
SUMMARY
Press Release 


2007

Despite More Cancer Drugs in R&D, Overall U.S. Approval Rate is 8%
September/October 2007, Vol.9, No.5
SUMMARY
Press Release 

Notable Gender & Racial Disparities Exist Among Clinical Investigators
November/December 2007, Vol.9, No.6
SUMMARY
Press Release 

Challenges Loom for Postmarketing Study Commitments; Benefits Unclear
May/June 2007, Vol. 9, No. 3
SUMMARY
Press Release 

Follow-On Drugs and Indications Play Key Role for World Health Organization
July/August 2007, Vol. 9, No. 4
SUMMARY
Press Release 

EMEA Meets Performance Goals, but Lags U.S. FDA in Drug Approvals
January/February 2007 Vol.9 No.1
SUMMARY
Press Release 

Pediatric Study Costs Rose Substantially from 2000 as Complexity Grew
March/April 2007 Vol. 9, No. 2
SUMMARY
Press Release